Menu
Recruiting NCT06787066

Sympathetic Vascular Transduction Across the Menopause Transition: Contributing Mechanisms

Early Phase I Interventional Menopause

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Propranolol Hydrochloride, Phentolamine Injection.
Who it may be relevant to
Registry conditions: Menopause. Basic parameters: 18 years — 70 years · Female.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Overview

The investigators aim to assess the interactions between the sympathetic nervous system and the vasculature in women across the menopause transition to better understand why aging women have a higher risk of cardiovascular disease.

Interventions

  • Drug Propranolol Hydrochloride
    Examine how IV propranolol impacts sympathetic transduction
  • Drug Phentolamine Injection
    Examine how IV phentolamine impacts sympathetic transduction

Primary outcome measures

  • Sympathetic transduction [Time frame: 1 day (single study visit)]
Secondary outcome measures (2)
  • Blood flow [Time frame: 1 day (single study visit)]
  • Muscle sympathetic nerve activity [Time frame: 1 day (single study visit)]

Eligibility criteria

Inclusion criteria

  • Assigned female at birth
  • 18-70 years of age
  • Body mass index (BMI) <30 kg/m2

Exclusion criteria

  • Assigned male at birth
  • Pregnancy, breastfeeding
  • Body mass index ≥30 kg/m2
  • Oral hormonal contraception in last 6 months, history of hormone replacement therapy, oophorectomy
  • Current smoking/nicotine use
  • Increased risk of bleeding, pro-coagulant disorders, clotting disorders, anticoagulation therapy
  • Nerve/neurologic disease
  • Cardiovascular, hepatic, renal, respiratory disease
  • Blood pressure ≥140/90 mmHg
  • Diabetes, Polycystic ovarian syndrome
  • Communication barriers
  • Prescription medications

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Allocation
N/A
Model
Single group
Masking
Open label
Primary purpose
Basic science

Study locations

United States · 1 center
  • University of Missouri — Columbia

Identifiers

NCT: NCT06787066 · 2125473

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗